XYD-8006

XYD-8006 is a novel, dual-payload antibody-drug conjugate (ADC) targeting A Disintegrin And Metalloproteinase 9 (ADAM9), a cell surface protease overexpressed in various solid tumors, including gastrointestinal and lung cancers. Developed by FDC Biotech, the molecule consists of a humanized anti-ADAM9 IgG1 monoclonal antibody conjugated via a high hydrophilic linker to two distinct potent payloads: a microtubule inhibitor and a topoisomerase I inhibitor. This dual-payload strategy is designed to enhance therapeutic efficacy and address challenges such as tumor heterogeneity and resistance to common single-payload ADC agents like DXD or SN38. Preclinical data presented at AACR 2026 demonstrated that XYD-8006 exhibits high specificity for ADAM9, efficient internalization, and superior tumor growth inhibition and regression across models with high, medium, and low ADAM9 expression. The drug is expected to enter clinical trials in 2026.